Upcoming Conferences

** All conferences are currently postponed or cancelled due to the ongoing COVID-19 pandemic. Further updates to our conference schedule will be made on a case-by-case basis or when safe travel is re-established. **

Sponsor – Styrene maleic acid lipid particles (SMALPs) offer a more stable and less disruptive alternative to conventional detergents for the study of membrane proteins. Conference site 

(w/ Frontier Scientific) National meeting for professional chemists. We’re looking forward to seeing all of the great scientific and techincal advances in the realm of chemistry. #ACSPhilly  Conference site

Exhibitor, Booth 1036 – this annual meeting brings together five scientific societies to explore the latest advances in biochemistry, molecular biology, pharmacology and more. #ExpBio @ExpBio Conference site

Exhibitor, Booth 220 (w/ Frontier Scientific) – additional details TBA Conference site

Sponsor – this workshop is a biennial gathering of scientists in the field of bioactive lipids. @8EWLM Conference site

Annual meeting for global leaders in clinical and laboratory medicine. Conference site

Sponsor – this FASEB Science Research Conference (SRC) focuses on lipid metabolism and translation of basic findings to clinical applications. Conference site



Current methods of extracting and separating phospholipids from biological sources are known to have considerable variation which makes downstream quantification difficult. In this study, we used a PI(4)P specific ELISA to examine the possible sources of this variation including the sample, extraction procedure, and presentation of the lipids. Results using Echelon’s PI(4)P ELISA show that the assay has a low coefficient of variation if the samples and lipids are presented in a standardized manner.

Lysosomal phospholipase A2 (LPLA2) is involved in both drug-induced phospholipidosis (DIPL) & drug-induced lupus (DIL), in which, tissue inflammation and organ
damage are observed. Here, we studied the charge & structure of the phospholipid substrate in relation to LPLA2 activity utilizing a self-quenched fluorogenic probe specifically designed for LPLA2 in acidic environment.

Autoantibodies to endogenous lipids can be readily found across a variety of tissues and have been implicated in autoimmune disease(s). Diagnosing these diseases typically relies on traditional techniques, such as ELISA, which may not adequately reproduce the in vivo presentation of lipids. Here, we examined several lipids involved in antiphospholipid syndrome (APS), an autoimmune disorder, and how their detection was impacted by the method of presentation.

Antibiotic resistance is an expanding issue worldwide and as such research into novel antibiotics remains a high priority. The synthesis of isoprenoids is vital to both bacteria and humans; however, bacteria have a distinct pathway to accomplish this, the MEP pathway. In this study, we used a combination of virtual and in vitro approaches to characterize a screen for the identification of novel MEP pathway inhibitors.

Drug-induced phospholipidosis (DIPL) is often triggered by the intake of cationic amphiphilic drugs (CADs), in which, resulted in lipid accumulation in lysosome. In this study, we explored a high-throughput enzymatic screening method targeting the activity of lysosomal phospholipase A2 (LPLA2), one of the enzymes responsible for normal lipid turnover and metabolism, in predicting DIPL.

Phospholipidosis (PL) is a condition of excessive accumulation of intracellular phospholipids by causing tissue inflammation and organ damage. PL is often triggered by cationic amphiphilic drug (CAD) such as amiodarone. In this study, we investigated if the activity of lysosomal phospholipase A2 (LPLA2), an enzyme previously showed involvement in drug-induced phospholipidosis (DIPL), can be used as a companion diagnostic biomarker for DIPL.

Scroll to Top